Strata Critical Medical (SRTA)
NASDAQ:SRTA
SRTA Stock Chart & Stats
$4.04
--
Market closed
$4.04
--
Day’s Range― - ―
52-Week Range$2.51 - $6.02
Previous CloseN/A
VolumeN/A
Average Volume (3M)773.89K
Market Cap
$351.44M
Enterprise Value$323.78M
Total Cash (Recent Filing)$61.23M
Total Debt (Recent Filing)$3.31M
Price to Earnings (P/E)9.6
Beta1.96
Next Earnings
May 12, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding86,989,140
10 Day Avg. Volume644,121
30 Day Avg. Volume773,894
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.42
Price to Sales (P/S)2.01
P/FCF Ratio-6.78
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue1.64
Enterprise Value/Gross Profit7.87
Enterprise Value/Ebitda-17.53
Forecast
1Y Price Target
$8.81Price Target Upside118.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.09
Revenue Forecast (FY)$269.18M
Bulls Say, Bears Say
Bulls Say
Strong Liquidity And Low LeverageA no-debt position combined with ~$61M of cash provides a durable financial buffer that supports operations, funds integration/A&M activity, and reduces refinancing risk. This liquidity allows management to pursue acquisition-led growth without immediate capital-market dependence, improving strategic optionality.
Robust Organic Logistics Growth And Margin RecoverySustained >35% organic logistics growth, alongside a 90% increase in Q4 gross profit and improving blended gross margins, indicates durable underlying demand and improving unit economics. If sustained, this supports long-term margin expansion and reduces reliance on one-off gains to drive profit.
Acquisition Platform Supported By Undrawn CreditAn undrawn $30M ABL (expandable to $50M) plus an explicit M&A strategy creates a structural pathway to accelerate scale and adjusted EBITDA. The facility, combined with asset-light fleet policy, lets management pursue bolt-ons to capture consolidation benefits and faster margin leverage over time.
Bears Say
Consistent Negative Operating Cash FlowPersistent negative operating and free cash flow increases dependence on cash reserves and external financing, limiting reinvestment and making growth more funding-sensitive. Continued cash burn could force asset sales, dilute shareholders or constrain M&A pacing if operating cash conversion does not improve.
Core Operating Losses (negative EBIT/EBITDA)Negative operating profitability despite revenue scale signals the business has not yet converted revenue into durable operating profit. Until EBIT/EBITDA turn sustainably positive, reported net income improvements remain fragile and the firm faces ongoing pressure to improve unit economics and cost structure.
Contingent Earn-out And Future Cash ObligationsContingent earn-outs (up to $45M) represent a sizable potential cash outflow that could materially pressure liquidity if triggered. These obligations add execution and timing risk, potentially competing with capital for acquisitions or operations and complicating cash planning over the next 12–24 months.
Strata Critical Medical News
SRTA FAQ
What was Strata Critical Medical’s price range in the past 12 months?
Strata Critical Medical lowest stock price was $2.51 and its highest was $6.02 in the past 12 months.
What is Strata Critical Medical’s market cap?
Strata Critical Medical’s market cap is $351.44M.
When is Strata Critical Medical’s upcoming earnings report date?
Strata Critical Medical’s upcoming earnings report date is May 12, 2026 which is in 30 days.
How were Strata Critical Medical’s earnings last quarter?
Strata Critical Medical released its earnings results on Mar 03, 2026. The company reported -$0.062 earnings per share for the quarter, missing the consensus estimate of $0.01 by -$0.072.
Is Strata Critical Medical overvalued?
According to Wall Street analysts Strata Critical Medical’s price is currently Undervalued.
Does Strata Critical Medical pay dividends?
Strata Critical Medical does not currently pay dividends.
What is Strata Critical Medical’s EPS estimate?
Strata Critical Medical’s EPS estimate is -0.04.
How many shares outstanding does Strata Critical Medical have?
Strata Critical Medical has 86,989,140 shares outstanding.
What happened to Strata Critical Medical’s price movement after its last earnings report?
Strata Critical Medical reported an EPS of -$0.062 in its last earnings report, missing expectations of $0.01. Following the earnings report the stock price went up 6.904%.
Which hedge fund is a major shareholder of Strata Critical Medical?
Currently, no hedge funds are holding shares in SRTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Strata Critical Medical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.81 (118.07% Upside)
$8.81 (118.07% Upside)
Blogger Sentiment
Bullish
SRTA Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
55.38%
12-Months-Change
Fundamentals
Return on Equity
16.46%
Trailing 12-Months
Asset Growth
29.27%
Trailing 12-Months
Company Description
Strata Critical Medical
Strata Critical Medical, Inc. provides time critical logistics solutions and specialized medical services to healthcare providers across the United States. The company operates as both an air and ground transporter of human organs for transplant. The company was formerly known as Blade Air Mobility, Inc. and change its name to Strata Critical Medical, Inc. in August 2025. The company was founded in 2014 and is headquartered in New York, New York.
SRTA Company Deck
SRTA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational momentum and financial improvement driven by robust organic logistics growth (35%+), a successful integration of the Keystone acquisition, significant gross profit and adjusted EBITDA improvement, and raised 2026 guidance. Key positives include no debt, a healthy cash balance (~$61M), an active M&A pipeline supported by an undrawn $30M facility, and regulatory trends that favor the company's DCD/NRP capabilities. Near-term weaknesses are largely execution and timing-related: a negative operating cash flow in Q4 driven by nonrecurring charges and working capital build from integration, a discrete aircraft corrosion/write-down, elevated SG&A from Keystone, and an anticipated sequential margin dip in Q1 due to mix and weather. Overall, the positives (sizable growth, margin improvement, guidance raises, strong balance sheet and strategic positioning) substantially outweigh the transient and integration-related lowlights.View all SRTA earnings summariesSRTA Stock 12 Month Forecast
Average Price Target
$8.81
▲(118.07% Upside)
Technical Analysis
―
AerSale Corporation
―
Sun Country Airlines Holdings
―
flyExclusive
―
Surf Air Mobility, Inc.
―
Ownership Overview
14.26% Insiders
10.96% Mutual Funds
<0.01% Other Institutional Investors
57.72% Public Companies and Individual Investors
Options Prices
Currently, No data available
---